

# BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

## Overview

2024/07/17 16:07:48	
<b>Price</b>	7.635 USD
<b>Difference</b>	<span style="color: green;">▲</span> 1.13% (0.09)

General attributes	
ISIN	CA0717341071
Symbol	BHC
Exchange	NYSE
Currency	USD
Sector	Other
Security type	Stock
Market cap (m)	2,540 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	7.63 USD (1,300)
Ask (Ask size)	7.64 USD (1,200)
Open	7.48 USD
High	7.655 USD
Low	7.44 USD
Close (prev. day)	7.55 USD
VWAP	7.557867 USD
Volume (pcs)	284,750
Trading volume	2,152,271.78
Number of trades	1,620
Last size	100

Futures and Options	
Related Futures	15
Related Options	-

PDF Downloads	
Company report: BAUSCH HEALTH COMPANIES INC.	<a href="#">Download</a>



Information about previous performance does not guarantee future performance.  
**Source:** FactSet

### Recent research

on sector			
Date		Headline	Download
2024/07/12		Global Equity Ratings	<a href="#">Download</a>
2024/06/21		Global Equity Ratings	<a href="#">Download</a>
2024/06/14		Global Equity Ratings	<a href="#">Download</a>
2024/05/29		Global Equity Ratings	<a href="#">Download</a>
2024/04/26		Global Equity Ratings	<a href="#">Download</a>

## Details

2024/07/17 16:07:48

## Price

7.635 USD

Difference ▲ 1.13% (0.09)

## General attributes

ISIN	CA0717341071
Symbol	BHC
Exchange	NYSE
Currency	USD
Sector	Other
Security type	Stock
Market cap (m)	2,540 EUR
Benchmark	S&P/TSX 60 INDEX

## Market data

Bid (Bid size)	7.63 USD (1,300)
Ask (Ask size)	7.64 USD (1,200)
Open	7.48 USD
High	7.655 USD
Low	7.44 USD
Close (prev. day)	7.55 USD
VWAP	7.557867 USD
Volume (pcs)	284,750
Trading volume	2,152,271.78
Number of trades	1,620
Last size	100

## Performance and Risk

	6m	1Y	3Y
Perf (%)	-10.12%	-10.44%	-72.65%
Perf (abs.)	-0.85	-0.88	-20.06
Beta	1.12	1.23	1.76
Volatility	38.64	39.53	68.71

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Price data

Ø price 5 days   Ø volume 5 days (pcs.)	7.432 USD (4,150,791)
Ø price 30 days   Ø volume 30 days (pcs.)	6.782 USD (2,533,379)
Ø price 100 days   Ø volume 100 days (pcs.)	8.028 USD (2,996,263)
Ø price 250 days   Ø volume 250 days (pcs.)	7.997 USD (2,690,564)
YTD High   date	11.460 USD (2024/04/03)
YTD Low   date	6.050 USD (2024/06/14)
52 Weeks High   date	11.460 USD (2024/04/03)
52 Weeks Low   date	6.050 USD (2024/06/14)

## All listings for BAUSCH HEALTH COMPANIES INC.

Exchange <span>⊕</span>	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/07/17	15:42	6.92 EUR	0.00	2
Toronto Stock Exchange	2024/07/17	16:07	10.44 CAD	0.39	263
Stuttgart	2024/07/17	09:29	6.831 EUR	0.00	2
SIX Swiss Exchange	2019/06/28	17:35	24.11 CHF	0.00	1
NYSE	2024/07/17	16:07	7.635 USD	2.15	1,620

	17						
Munich	2024/07/17	08:01	6.843	EUR	0.00		1
Frankfurt	2024/07/17	08:14	6.84	EUR	0.00		1
Duesseldorf	2024/07/17	08:10	6.836	EUR	0.00		1
Berlin	2024/07/17	08:01	6.843	EUR	0.00		1

## Company profile

### Company Logo



### Contact Details

BAUSCH HEALTH COS. INC.

--

2150 St. Elzéar Boulevard West - H7L 4A8  
Laval

Telefon: +1-514-744-6792

Fax: +

E-mail: -

### PDF Downloads

Company report: BAUSCH HEALTH  
COMPANIES INC.



### Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

### Members of Management Board

Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee
Seana Carson	Member of Executive Committee
Tom Vadaketh	Member of Executive Committee

### Board of directors

John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Christian Garcia	Member of Supervisory Board
Frank Lee	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board